Last week, regulators in the U.S. and Europe disclosed that the same carcinogen that led to numerous recalls over the past year of valsartan and similar blood pressure pills was found in Zantac and other antacid medicines known as ranitidines. The Food and Drug Administration, however, was first alerted to the presence of the carcinogen, known as NDMA, by Valisure, a small online pharmacy that also tests batches of each medicine it sells. We spoke with David Light, a co-founder and chief executive officer, about the decision to look for NDMA and why he believes that regulators are failing to characterize the problem properly. This is an edited version of the conversation.

Pharmalot: You sell medicines online, but how and why did your company start testing them?

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy